We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Since 2008, there has been no “consistent increase” in ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with tumor necrosis factor inhibitors experienced a shorter time until cancer progression.

Reducing the dose of biologic drugs may not match standard treatment in preventing disease flares at 1 year in patients with rheumatoid arthritis in remission, a phase 4 study finds.

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints (those between the spine and hipbone). Less commonly, AS can affect other joints such ...

Relapse occurred in over half of patients with juvenile idiopathic arthritis (JIA) within a year of stopping biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) treatment after ...

RA RA patients treated with biologics have exhibited either clinical remission or low disease activity on follow-up visits. Most patients diagnosed with rheumatoid arthritis (RA) and treated with ...

Patients with psoriatic arthritis who received bDMARDs vs cDMARDs had a lower risk for major adverse cardiovascular events, all-cause mortality, and cardiovascular mortality. Biologic ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...